Summary
Biomarker studies in prostate cancer research aim to discover new markers or novel uses of prostate-specific antigen (PSA) to complement or replace PSA as the existing standard for screening. These studies often report as primary endpoint the operating characteristics of the new marker and in some cases, make a direct comparison to PSA on the same subject population. Due to the widespread use of PSA for referral to more definitive prostate cancer diagnosis in the United States, it is easy to encounter pitfalls in the design and analysis of such studies, including failure to assess the incremental value of a new marker to PSA or failure to adjust for verification bias (use of PSA for disease ascertainment). This chapter covers four such commonly seen pitfalls in biomarker studies in prostate cancer screening and provides methods for avoiding or correcting the associated biases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Thompson, I.M., Pauler, D.K., Goodman, P.J., Tangen, C.M., Lucia, S.M., Parnes, H.L., Minasian, L.M., Ford, L.G., Lippman, S.M., Crawford, E.D., Crowley, J.J., and Coltman, C.A., Jr. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level \(\leq\) 4.0 ng per milliliter New England Journal of Medicine 350, 2239–46.
Thompson, I.M., Ankerst, D.P., Chi, C., Lucia, M.S., Goodman, P., Crowley, J.J., Parnes, H.L., and Coltman, C.A., Jr. (2005) The operating characteristics of prostate-specific antigen in a population with initial PSA of 3.0 ng/ml or lower Journal of the American Medical Association 294, 66–70.
Ankerst, D.P., Thompson, I.M. (2007) Understanding mixed messages about prostate specific antigen: biases in the evaluation of cancer biomarkers Journal of Urology 177, 426–7.
Etzioni, R.D., Ankerst, D.P., Thompson, I.M. (2007) Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability Journal of the National Cancer Institute 99, 489–90.
Etzioni, R.D., Ankerst, D.P., Thompson, I.M., et al. (2007b) Is PSA velocity useful in early detection of prostate cancer? A critical appraisal of the evidence Journal of the National Cancer Institute, 99, 1510–5.
DeLong E.R., DeLong D.M., Clarke-Pearson D.L. (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44, 837–45.
Benson, M.C., Whang, I.S., Olsson, C.A., et al. (1992) The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen Journal of Urology 147, 817–21.
Carter, H.B., Pearson, J.D., Metter, E.J. et al. (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease Journal of the American Medical Association 267, 2215–20.
Schmid, H.P. (1995) Tumour markers in patients on deferred treatment: prostate specific antigen doubling times Cancer Surveys 23, 157–67.
Carter, H.B., Ferrucci, L., Ketterman, A., Landis, P., Wright, E.J., Epstein, J.I., Trock, B.J., Metter, E.J. (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability Journal of the National Cancer Institute 98, 1521–7.
Kundu, S.D., Roehl, K.A., Yu, X, Antenor, J.A., Suarez, B.K., Catalona, W.J. (2007) Prostate specific antigen density correlates with features of prostate cancer aggressiveness Journal of Urology 177, 505–9.
Moul, J.W., Sun, L., Hotaling, J.M., et al. (2007) Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening Journal of Urology 177, 499–503.
Thompson, I. M., Ankerst, D.P., Chi, C., Goodman, P.J., Tangen, C.M., Lucia, M.S., Feng, Z., Parnes, H.L., and Coltman, C.A., Jr. (2006) Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial Journal of the National Cancer Institute 98, 529–34.
Fall, K., Garmo, H., Andren, O., Bill-Axelson, A., Adolfsson, J., Adami, H.O., Johansson, J.E., Holmberg, L. (2007) Prostate specific antigen levels as a predictor of lethal prostate cancer Journal of the National Cancer Institute 99, 526–32.
Roobol, M.J., Kranse, R., de Koning, H.J., Schroeder, F.H. (2004) Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (Rotterdam) Urology 63, 309–15.
Schroeder, F.H., Roobol, M.J., van der Kwast, T.H., Kranse, R., and Bangma, C.H. (2006) Does PSA velocity predict prostate cancer in pre-screened populations? European Urology 49, 460–5.
Catalona, W.J., Smith, D.S., Wolfert, R.L. et al. (1995) Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening Journal of the American Medical Association 274, 1214–20.
Partin, A.W., Brawer, M.K., Bartsch, G. et al. (2003) Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial Journal of Urology 170, 1787–91.
Mikolajczyk, S.D., Rittenhouse, H.G. (2004) Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease Rinsho Byori 52, 223–30.
Khan, M.A., Sokoll, L.J., Chan, D.W. et al. (2004) Clinical utility of proPSA and “benign” PSA when percent free PSA is less than 15% Urology 64, 1160–4.
Etzioni, R., Falcon, S., Gann, P.H., Kooperberg, C.L., Penson, D.F., Stampfer, M.J. (2004) Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? Cancer Epidemiology, Biomarkers and Prevention 13, 1640–5.
Punglia, R.S., D’Amico, A.V., Catalona, W.J., Roehl, K.A., Kuntz, K.M. (2003) Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen New England Journal of Medicine 349, 335–42.
Fitzmaurice GM, Laird NM, Ware JH (2004) Applied Longitudinal Analysis. New Jersey: John Wiley & Sons.
Rotnitzky A., Faraggi D., Schisterman E. (2006) Doubly robust estimation of the area under the receiver-operating characteristic curve in the presence of verification bias Journal of the American Statistical Association 101, 1276–88.
Wang, X., Yu, J., Sreekumar, A. et al. (2005) Autoantibody signatures in prostate cancer New England Journal of Medicine, 353, 1224–35.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Ankerst, D.P. (2009). Pitfalls in Prostate Cancer Biomarker Evaluation Studies. In: Ankerst, D.P., Tangen, C.M., Thompson, I.M. (eds) Prostate Cancer Screening. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-60327-281-0_23
Download citation
DOI: https://doi.org/10.1007/978-1-60327-281-0_23
Publisher Name: Humana Press
Print ISBN: 978-1-60327-280-3
Online ISBN: 978-1-60327-281-0
eBook Packages: MedicineMedicine (R0)